James A. Monn - Concepedia

Author

James A. Monn

Eli Lilly (United States)

Also Known As

James A Monn, James A. Monn

Publications

908

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)

About

James A. Monn is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	361
2	Social Sciences	4	4	315
3	Biochemistry	1	1	15
4	Endocrinology	1	1	19
5	Neurology	1	1	43

James A. Monn

Publications

908

Citations

H-Index

Page 1

	Year	Citations
Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex Gerard J. Marek, Rebecca A. Wright, Darryle D. Schoepp, Journal of Pharmacology and Experimental Therapeutics	2000	279
The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats Jayne Cartmell, James A. Monn, Darryle D. Schoepp Journal of Pharmacology and Experimental Therapeutics	1999	268
In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats Giuseppe Battaglia, James A. Monn, Darryle D. Schoepp Neuroscience Letters Vivo InhibitionNeurophysiologyMedicineSynaptic TransmissionPhysiology	1997	163
The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing Jayne Cartmell, James A. Monn, Darryle D. Schoepp European Journal of Pharmacology Behavioral NeuroscienceAddictionMedicineFunctional SelectivityPsychopharmacology	2000	90
Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia Amy G.M Lam, Marc A. Soriano, James A. Monn, Neuroscience Letters NeurophysiologyMedicineNeuropharmacologyExperimental PharmacologyPharmacotherapy	1998	43
Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Naunyn-Schmiedeberg s Archives of Pharmacology Functional SelectivityMedicineSynaptic TransmissionNeuropeptide ReceptorNeuropharmacology	1998	31
Effects of LY354740, a Novel Glutamatergic Metabotropic Agonist, on Nonhuman Primate Hypothalamic-Pituitary-Adrenal Axis and Noradrenergic Function Jeremy D. Coplan, Sanjay J. Mathew, Eric L. Smith, CNS Spectrums PsychopharmacologyPharmacotherapyExperimental PharmacologySocial SciencesNeuroendocrine Mechanism	2001	19
Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid Matthew J. Valli, Darryle D. Schoepp, Rebecca A. Wright, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryFunctional SelectivityMedicineMechanism Of Action	1998	15

Page 1